• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经递质在帕金森病相关精神病发展中的作用。

The role of neurotransmitters in the development of Parkinson's disease-related psychosis.

机构信息

Department of Neurology, Emory University School of Medicine, Atlanta, GA.

Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Eur J Neurol. 2017 Oct;24(10):1244-1254. doi: 10.1111/ene.13376. Epub 2017 Jul 31.

DOI:10.1111/ene.13376
PMID:28758318
Abstract

Psychotic symptoms are common, disabling non-motor features of Parkinson's disease (PD). Despite noted heterogeneity in clinical features, natural history and therapy response, current dogma posits that psychosis generally progresses in a stereotypic manner through a cascade of events that begins with minor hallucinations and evolves to severe hallucinations and delusions. Further, the occurrence of psychotic symptoms is believed to indicate a poor prognosis. Here we propose a classification scheme that outlines the pathogenesis of psychosis as it relates to dysfunction of several neurotransmitter systems. We hypothesize that several subtypes exist, and that PD psychosis is not consistently indicative of a progressive cascade and poor prognosis. The literature was reviewed from 1990 to 2017. An overview of the features of PD psychosis is followed by a review of data indicating the existence of neurotransmitter-related subtypes of psychosis. We found that ample evidence exists to demonstrate the presence of multiple subtypes of PD psychosis, which are traced to dysfunction of the following neurotransmitter systems: dopamine, serotonin and acetylcholine. Dysfunction of each of these systems is recognizable through their clinical features and correlates, and the varied long-term prognoses. Identifying which neurotransmitter system is dysfunctional may help to develop targeted therapies. PD psychosis has various subtypes that differ in clinical features, underlying pathology and pathophysiology, treatment response and prognosis. A novel classification scheme is presented that describes the clinical subtypes with different outcomes, which could lead to the development of targeted therapies. Future research should focus on testing the viability of this classification.

摘要

精神病症状是常见的,也是帕金森病(PD)的非运动性致残特征。尽管临床特征、自然病史和治疗反应存在明显异质性,但目前的定论认为,精神病通常通过一系列事件以刻板的方式进展,这些事件始于轻微的幻觉,发展为严重的幻觉和妄想。此外,精神病症状的发生被认为预示着预后不良。在这里,我们提出了一个分类方案,概述了与几种神经递质系统功能障碍相关的精神病发病机制。我们假设存在几种亚型,并且 PD 精神病并不总是表明存在进行性级联和不良预后。对 1990 年至 2017 年的文献进行了回顾。概述了 PD 精神病的特征,随后回顾了表明存在与神经递质相关的精神病亚型的数据。我们发现,有充分的证据表明 PD 精神病存在多种亚型,这些亚型可追溯到以下神经递质系统的功能障碍:多巴胺、血清素和乙酰胆碱。这些系统的每个系统的功能障碍都可以通过其临床特征和相关性以及不同的长期预后来识别。确定哪个神经递质系统功能障碍可能有助于开发靶向治疗。PD 精神病有多种亚型,在临床特征、潜在病理和病理生理学、治疗反应和预后方面存在差异。提出了一种新的分类方案,描述了具有不同结局的临床亚型,这可能导致靶向治疗的发展。未来的研究应侧重于测试这种分类的可行性。

相似文献

1
The role of neurotransmitters in the development of Parkinson's disease-related psychosis.神经递质在帕金森病相关精神病发展中的作用。
Eur J Neurol. 2017 Oct;24(10):1244-1254. doi: 10.1111/ene.13376. Epub 2017 Jul 31.
2
Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.全面识别帕金森病精神病中的妄想和嗅觉、触觉、味觉及轻度幻觉。
Parkinsonism Relat Disord. 2018 Sep;54:40-45. doi: 10.1016/j.parkreldis.2018.04.008. Epub 2018 Apr 4.
3
Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management.视觉幻觉与帕金森病药物治疗的作用:触发因素、病理生理学和管理。
J Neuropsychiatry Clin Neurosci. 2020 Fall;32(4):334-343. doi: 10.1176/appi.neuropsych.19110316. Epub 2020 May 6.
4
Cognitive correlates of hallucinations and delusions in Parkinson's disease.帕金森病中幻觉和妄想的认知关联
J Neurol Sci. 2014 Dec 15;347(1-2):316-21. doi: 10.1016/j.jns.2014.10.033. Epub 2014 Oct 23.
5
Hallucinations and the spectrum of psychosis in Parkinson's disease.帕金森病中的幻觉与精神病谱系
J Neurol Sci. 2017 Mar 15;374:56-62. doi: 10.1016/j.jns.2017.01.014. Epub 2017 Jan 5.
6
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.治疗帕金森病精神病相关的幻觉和妄想。
Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z.
7
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.帕金森病性精神病作为一种5-羟色胺-多巴胺失衡综合征
CNS Spectr. 2016 Oct;21(5):355-359. doi: 10.1017/S1092852916000602.
8
Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.帕金森病中精神病性症状的患病率及其临床相关性:一项基于社区的研究。
Arch Neurol. 1999 May;56(5):595-601. doi: 10.1001/archneur.56.5.595.
9
Parkinson's disease psychosis 2010: a review article.帕金森病精神病 2010:一篇综述文章。
Parkinsonism Relat Disord. 2010 Nov;16(9):553-60. doi: 10.1016/j.parkreldis.2010.05.004. Epub 2010 Jun 9.
10
Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.帕金森病非痴呆患者的精神病特征、相关性和评估。
Parkinsonism Relat Disord. 2017 Oct;43:56-60. doi: 10.1016/j.parkreldis.2017.07.011. Epub 2017 Jul 15.

引用本文的文献

1
Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson's Disease.中枢胆碱能神经系统在帕金森病运动和非运动症状中的作用
Curr Neuropharmacol. 2025;23(10):1232-1248. doi: 10.2174/011570159X368923250313045859.
2
Clinical features, plasma neurotransmitter levels and plasma neurohormone levels among patients with early-stage Parkinson's disease with sleep disorders.早期帕金森病伴睡眠障碍患者的临床特征、血浆神经递质水平及血浆神经激素水平
Cell Commun Signal. 2025 Mar 18;23(1):144. doi: 10.1186/s12964-025-02153-8.
3
The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson's disease.
在帕金森病双侧大鼠模型中,血清素投射通路的化学遗传靶向对左旋多巴诱导的运动障碍和精神病的影响。
Front Neural Circuits. 2024 Nov 14;18:1463941. doi: 10.3389/fncir.2024.1463941. eCollection 2024.
4
The High-Precision Liquid Chromatography with Electrochemical Detection (HPLC-ECD) for Monoamines Neurotransmitters and Their Metabolites: A Review.用于单胺类神经递质及其代谢产物的高精度液相色谱-电化学检测法(HPLC-ECD)综述
Molecules. 2024 Jan 19;29(2):496. doi: 10.3390/molecules29020496.
5
Drug delivery for neurodegenerative diseases is a problem, but lipid nanocarriers could provide the answer.用于神经退行性疾病的药物输送是一个问题,但脂质纳米载体可能提供答案。
Nanotheranostics. 2024 Jan 1;8(1):90-99. doi: 10.7150/ntno.88849. eCollection 2024.
6
Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson's Disease.早期帕金森病精神症状的综合评估及其临床相关性。
J Parkinsons Dis. 2023;13(7):1185-1197. doi: 10.3233/JPD-230056.
7
Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.基于文献的发现表明抗组胺药是一种有前途的帕金森病辅助治疗药物。
Int J Mol Sci. 2023 Aug 2;24(15):12339. doi: 10.3390/ijms241512339.
8
Solution- and gas-phase study of binding of ammonium and bisammonium hydrocarbons to oxacalix[4]arene carboxylate.铵和双铵烃与氧杂杯[4]芳烃羧酸盐结合的溶液相和气相研究。
RSC Adv. 2023 Jan 4;13(2):1041-1048. doi: 10.1039/d2ra07614d. eCollection 2023 Jan 3.
9
Therapeutic Effects of Quetiapine and 5-HT Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice.喹硫平与 5-羟色胺受体激动剂对多巴胺缺乏小鼠多动的治疗作用。
Int J Mol Sci. 2022 Jul 4;23(13):7436. doi: 10.3390/ijms23137436.
10
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.奥匹卡朋,一种新型儿茶酚-O-甲基转移酶抑制剂,用于治疗帕金森病的“关”期发作。
Health Psychol Res. 2022 Jun 28;10(3):36074. doi: 10.52965/001c.36074. eCollection 2022.